In our study, SOX11 expression levels in ACC, COAD, ESCA, TGCT and UVM showed an increasing trend with increasing tumor stage, but the trend was more pronounced mainly in tumor stages I-III which might be due to the small sample size of stage IV patients. Here, SOX11 is linked to adrenal cortex carcinoma.